<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00854256</url>
  </required_header>
  <id_info>
    <org_study_id>iScience-022-CG</org_study_id>
    <nct_id>NCT00854256</nct_id>
  </id_info>
  <brief_title>Trabeculectomy Versus Canaloplasty to Treat Glaucoma</brief_title>
  <official_title>Comparison of Canaloplasty and Trabeculectomy in Patients With Open Angle Glaucoma and Inadequate Local Eye Pressure Lowering Therapy - a Prospective, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>iScience Interventional Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate pressure lowering effect of two surgical methods&#xD;
      canaloplasty and trabeculectomy in patients with open angle glaucoma, in which under local&#xD;
      pressure lowering therapy the progression of the disease could not be stopped, and thus a&#xD;
      pressure lowering surgical intervention is necessary. The risks in the postoperative course&#xD;
      in Canaloplasty in the literature as lower than for the trabeculectomy with mitomycin-C.&#xD;
      Conversely, large glaucoma centers questioning the effectiveness of permanent pressure&#xD;
      lowering of canaloplasty. Precisely this question is investigated in the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eye pressure</measure>
    <time_frame>Within 12 month after surgery</time_frame>
    <description>Eye pressure is measured after 1 month, 2 months, 3 months, 6 months, 9 months, and 12 months after surgery.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Canaloplasty</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Trabeculectomy with mitomycin C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Canaloplasty</intervention_name>
    <description>Canaloplasty surgery</description>
    <arm_group_label>Canaloplasty</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trabeculectomy with mitomycin C</intervention_name>
    <description>Trabeculectomy with mitomycin C surgery</description>
    <arm_group_label>Trabeculectomy with mitomycin C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with open angle glaucoma and excavation of 0.4 - 0.8&#xD;
&#xD;
          -  60 eyes of 60 patients (30 patients for trabeculectomy, 30 patients for Canaloplasty)&#xD;
             The ratio of female / male is not involved.&#xD;
&#xD;
          -  Eye pressure under local therapy: 20mmHg and above (corrected with pachymetry table).&#xD;
&#xD;
          -  Local drug therapy: at least 2 eye pressure lowering ingredients or absolute&#xD;
             intolerance to preservatives or eye drops.&#xD;
&#xD;
          -  general anesthesia possible.&#xD;
&#xD;
          -  The operation must be signed by the surgeon as a state-of-the-art performed without&#xD;
             complication to be evaluated. If the operation does not meet this criterion, the&#xD;
             patient is excluded from the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  all patients are not included in the group of inclusion criteria, or:&#xD;
&#xD;
          -  Phenprocoumon therapy.&#xD;
&#xD;
          -  operation is not done state-of-the-art.&#xD;
&#xD;
          -  after the surgery: additional eye pressure lowering surgery, cataract surgery,&#xD;
             keratoplasty, laser surgery in the anterior eye segment (except suture lysis after&#xD;
             trabeculectomy)&#xD;
&#xD;
          -  Uveitis, or possible inflammation of the eye&#xD;
&#xD;
          -  Previous eye pressure lowering operations or laser interventions&#xD;
&#xD;
          -  Corneal Refractive Surgery (pseudophakia allowed)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gerhard Welsandt, MD</last_name>
    <phone>+49-221-478-0</phone>
    <email>g.welsandt@uni-koeln.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre of Ophthalmology, University of Cologne</name>
      <address>
        <city>Cologne</city>
        <state>NRW</state>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>March 2, 2009</study_first_submitted>
  <study_first_submitted_qc>March 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2009</study_first_posted>
  <last_update_submitted>April 12, 2013</last_update_submitted>
  <last_update_submitted_qc>April 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2013</last_update_posted>
  <responsible_party>
    <name_title>Gerhard Welsandt, MD</name_title>
    <organization>University of Cologne</organization>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

